Skip to main content
    N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $160.21
    -0.29 (-0.18%)

    Market Cap: $303.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novartis AG ADR (NVS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Novartis AG ADR (NVS) to earn $9.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $57.76B. Of 11 analysts, 5 rate the stock Buy or Strong Buy, 4 Hold and 2 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $9.93.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.55, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 45% of the ratings.

    RatingAnalystsShare
    Strong Buy327.3%
    Buy218.2%
    Hold436.4%
    Sell19.1%
    Strong Sell19.1%
    Consensus
    Hold
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 9.5% and revenue estimates rise 6.8%.

    Fiscal year ending Dec 31, 2026
    $9.07
    EPS consensus, revenue $57.76B
    Fiscal year ending Dec 31, 2027
    $9.93
    EPS consensus, revenue $61.71B
    Fiscal year ending Dec 31, 2028
    $10.75
    EPS consensus, revenue $64.05B

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$9.07$8.67 to $9.388$57.76B$56.47B to $58.86B19
    Dec 31, 2027$9.93$9.30 to $10.499$61.71B$59.72B to $64.71B20
    Dec 31, 2028$10.75$10.41 to $11.247$64.05B$62.50B to $66.29B8

    Quarterly Estimates

    The EPS consensus is $2.27 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.27$2.05 to $2.4312$15.01B$13.89B to $16.00B13
    Mar 31, 2027$2.27$2.21 to $2.332$14.31B$14.05B to $14.57B2

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202751

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.8% from $8.82.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$9.07$9.16$8.83$8.85$8.82+2.8%
    Fiscal year ending Dec 31, 2027$9.93$9.94$9.80$9.84$9.87+0.6%
    Quarter ending Mar 31, 2027$2.27$2.27$2.33$2.33$2.33-2.6%

    Frequently Asked Questions About NVS

    What is the NVS stock forecast?

    Consensus analyst estimates put Novartis AG ADR's EPS at $9.07 for the fiscal year ending Dec 31, 2026, on revenue of $57.76B. The consensus rating from 11 analysts is Hold.

    How do analysts rate NVS stock?

    Of 11 analysts covering Novartis AG ADR, 3 rate it Strong Buy, 2 Buy, 4 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from NVS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.07, with estimates from $8.67 to $9.38 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.93, with estimates from $9.30 to $10.49 from 9 analysts.

    What revenue do analysts expect from Novartis AG ADR next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $57.76B, with estimates from $56.47B to $58.86B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $61.71B, with estimates from $59.72B to $64.71B.

    How many analysts cover NVS?

    11 analysts rate Novartis AG ADR stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.